We are an independent international pharmaceutical company, innovating for and with patients. Being governed by a non-profit foundation gives us a patient-centric long-term vision; concretely, we prioritize long-term innovation for patients by reinvesting 100% of our profit in the development of the company. We are committed to advancing healthcare and creating a meaningful social impact, for a more sustainable world. As a result, patients are the ultimate beneficiaries of this uncommon and differentiated approach.  

Our Patient-Centric approach is driven by Innovation and digital solutions. We bring breakthrough innovation in hard-to-treat diseases and incremental innovation in chronic diseases. In Oncology, as of today:  We use precision medicine, backed by ‘companion diagnostics’, to create breakthrough drugs, 70% of our R&D budget being committed to oncology, focusing on gastro-intestinal cancers, In Neurology, in the medium-term, we will leverage our successes in Oncology, using the same precision medicine approach, which should also work particularly well in neurodegenerative diseases, a TA with no new drugs in over 50 years. In chronic cardiovascular diseases, we have a holistic portfolio approach, our single pill combinations being a game changer for therapeutic adherence: WHO estimates that if every patient with a chronic disease followed their treatment exactly, 200,000 deaths would be avoided each year in Europe.

As a global player, we manage all our activities efficiently for the ultimate benefit of patients with significant assets in each therapy area and geography, creating value and making us a partner of choice. As a mid-size pharma company, we invest more resources in fewer projects, ensuring continuity and a long-term perspective in partnerships, promoting short decision-making circuits with accessible leaders and top managers, over 70 strategic alliances with other pharma companies, biotech companies and academics worldwide to accelerate innovation.